Compare Amphastar Pharmaceuticals Inc (AMPH) vs Simon Property Group Inc (SPG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Simon Property Group Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Simon Property Group Inc trades at $218 (market cap $70.94B). The key difference: Simon Property Group Inc is far larger — about 85.9× Amphastar Pharmaceuticals Inc's market cap, and Simon Property Group Inc pays a 4.02% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SPG | |
|---|---|---|
Market Cap | $826.08M | $70.94B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $227.56 |
52-Week Low | $16.87 | $159.93 |
Enterprise Value | $1.22B | $99.42B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Simon Property Group (SPG) trades at $218.77, down 0.43% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 70.59% net income margin and has beaten earnings estimates in three consecutive quarters. Recent news highlights robust Q1 2026 results and a dividend payout of $2.25 for H1-26.
Outlook remains positive due to strong leasing and redevelopment, but risks include high debt levels and e-commerce competition. Analyst consensus is mixed with a $214.40 price target, slightly below current levels, suggesting cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
